Total Voting Rights
Hammerson plc (the "Company" or "Hammerson")
Total Voting Rights and Capital
4 December 2024
Further to the announcement made by the Company on Wednesday, 16 October 2024 regarding the commencement of a programme to purchase ordinary shares of 5 pence each in the capital of the Company ("Ordinary Shares" and the "Share Buyback Programme"), Hammerson confirms that 746,437 Ordinary Shares were delivered to the Company and immediately cancelled on Wednesday, 4 December 2024. These shares represent the aggregate number of purchases made pursuant to the Share Buyback Programme from Monday, 25 November 2024 to Friday, 29 November 2024 (inclusive).
In accordance with the requirements of the FCA's Disclosure Guidance and Transparency Rule 5.6.1A, the Company hereby notifies the market that the Company's issued share capital as at Wednesday, 4 December 2024, consists of 494,538,279 Ordinary Shares, of which 1,300,825 shares are held in treasury. Therefore, the total number of voting rights in the Company as at Wednesday, 4 December 2024, is 493,237,454. This figure should be used by Shareholders as the denominator for calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, Ordinary Shares under the FCA's Disclosure Guidance and Transparency Rules and/or the Irish Transparency (Directive 2004/109/EC) Regulations 2007, as amended.
For further information contact:
Richard Crowle
Senior Assistant Company Secretary
+44 (0) 20 7887 1000
The announcement above has also been released on the SENS system of the Johannesburg Stock Exchange and on Euronext Dublin.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.